MENU
ACTU
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Actuate Therapeutics (ACTU) Ownership - Who owns Actuate Therapeutics?
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3)... Show more
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
154.57M
P/E Ratio
N/A
Total Cash
6.49M
Projected Growth
N/A
Total Debt
N/A
Revenue
N/A
Risk (Beta)
N/A
Dividend Yield
N/A
Total Cash/Share
0.28
Total Debt/Equity
N/A
Revenue/Share
null USD as % of share price
Fundamentals
ACTU
Capitalization
155M
P/E Ratio
N/A
Risk (Beta)
N/A
Dividend Yield
N/A
Total Cash
6.49M
Total Cash/Share
0.28
Total Debt
N/A
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0%
Revenue
0
ROE
N/A
Book Value
-2.65M
P/B Ratio
2000.00
Cash Flow
N/A
Earnings
-3.11
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
20
Current Ratio
0.73
Current Revenue Per Employee
N/A
Dividends Per Share - Security
N/A
EBITDA
-24.66M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-567.45
Shares Held By Institutions
70.6M
Shares Outstanding - Current
23.2M
Total Liabilities
9.62M
Total Volume MTD
N/A
Value
-1
Gain YTD
-16.457
View a ticker or compare two or three
VS
VS
Show more...
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. ACTU showed earnings on September 03, 2025. You can read more about the earnings report here.
A.I. Advisor
published General Information